Intelligent Bio Solutions Inc. INBS

Intelligent Bio Solutions submits comprehensive clinical data to enter US drug screening market. Clinical data submission advances regulatory approval process for major US market entry.

Intelligent Bio Solutions Inc. submitted an FDA 510(k) package for its Intelligent Fingerprinting Drug Screening System to obtain U.S. market clearance. FDA submission advances potential U.S. market entry for core drug screening product with major implications for growth.

Intelligent Bio Solutions achieves above 98% accuracy in method comparison study supporting 2026 FDA 510(k) submission. High accuracy result strengthens path to FDA approval and market entry for core product.

Intelligent Bio Solutions Inc. (INBS) announces private placement of up to $15 million to a single existing institutional investor priced at-the-market under Nasdaq rules. Private placement secures up to $15 million in capital that may support operations and influence financial position.

Intelligent Bio Solutions Inc. achieved 38% year-over-year revenue growth for fiscal 2026, fueled by expansion in its reader installed base and high-margin cartridge sales. Revenue growth of 38% signals stronger operational results and product demand for the company.

Intelligent Bio Solutions Inc. completed a method comparison study for the Intelligent Fingerprinting Drug Screening System. Study completion marks a product development milestone that may support future regulatory progress for the drug screening system.

Intelligent Bio Solutions Inc. completed a usability study supporting its FDA 510(k) submission. Usability study completion advances INBS toward potential FDA clearance and product commercialization.

Intelligent Bio Solutions completes interference study assessing impact of everyday substances on its Intelligent Fingerprinting System. Completion of the study provides validation data supporting reliability of the company's core fingerprinting technology.

Intelligent Bio Solutions achieves key milestone ahead of planned FDA 510(k) submission, advancing toward U.S. market entry. Milestone before FDA submission advances company toward U.S. market entry.

Intelligent Bio Solutions completed precision testing, strengthening its FDA 510(k) submission package ahead of planned entry into the multi-billion-dollar U.S. drug screening market. Precision testing completion advances FDA submission and positions company for major market entry with significant revenue potential.

Intelligent Bio Solutions Inc. (INBS) initiates clinical study to support FDA clearance and planned U.S. market entry. Clinical study initiation advances INBS toward FDA approval and U.S. market expansion.

Intelligent Bio Solutions Inc. (INBS) starts multi-site method comparison study for FDA 510(k) submission. FDA study launch marks key regulatory step that can shift company trajectory and investor sentiment.

Intelligent Bio Solutions Inc. (INBS) reported 46% year-over-year revenue growth in its fiscal third quarter. 46% year-over-year revenue growth indicates strong financial momentum capable of significantly enhancing investor sentiment and market performance.

Intelligent Bio Solutions Inc. (INBS) initiates validation study for rapid drug screening cartridge targeting 70% faster results. Initiating validation for a 70% faster drug screening cartridge advances core product innovation and competitive positioning for INBS.

Intelligent Bio Solutions Inc. (INBS) advances its upcoming FDA 510(k) submission after successfully completing penetration testing with no major vulnerabilities identified. Advancing FDA 510(k) submission and clearing penetration testing marks significant regulatory progress that could accelerate product commercialization and improve market positioning for INBS.

Intelligent Bio Solutions Inc. (INBS) completed its clinical cut-off study and advanced its FDA 510(k) clinical program, targeting the multi-billion-dollar U.S. drug screening market. Advancing FDA 510(k) program completion signals major progress toward regulatory approval and market entry in a multi-billion-dollar sector.

Intelligent Bio Solutions Inc. (INBS) received its eighth patent grant in Europe, strengthening its intellectual property portfolio in the region. Eighth European patent grant moderately bolsters INBS's IP protection and competitive edge in a key market.

Intelligent Bio Solutions Inc. (INBS) successfully manufactured and shipped first readers with new partner, accelerating scale and driving gross margin expansion ahead of planned U.S. entry. First reader shipments with new partner accelerate scaling, expand margins, and position INBS for U.S. market entry, significantly boosting future performance and investor sentiment.

Intelligent Bio Solutions Inc. (INBS) partners with Bouygues UK, subsidiary of multi-billion dollar global construction giant Bouygues Construction, to roll out drug testing solutions across UK operations. Strategic partnership with major construction firm accelerates INBS international expansion and validates drug testing technology in new market.

Intelligent Bio Solutions Inc. reported a record fiscal second quarter revenue growth of 48%, driven by a 104% year-over-year surge in reader sales. This significant increase highlights the company's strong market performance and demand for its products. The substantial revenue growth and surge in sales indicate a significant positive shift in the company's market position and investor sentiment.

Intelligent Bio Solutions Inc. (INBS) anticipates a revenue growth of approximately 48% year-over-year for the fiscal second quarter of 2026, projecting total revenue to exceed $2 million for the first half of the fiscal year. This growth reflects the company's ongoing expansion and positive market response to its offerings. Projected revenue growth indicates significant improvement in financial performance and market positioning.

Intelligent Bio Solutions Inc. has initiated additional clinical studies to support its FDA 510(k) submission, aiming for entry into the multi-billion dollar U.S. market. This move is part of the company's strategy to enhance its product offerings and capitalize on significant market opportunities. The initiation of clinical studies for FDA submission represents a significant strategic move that could alter the company's market positioning and investor sentiment.

Intelligent Bio Solutions Inc. has successfully closed a private placement of $10.0 million, priced at-the-market under Nasdaq rules. The funds raised are intended to support the company's growth initiatives and operational needs. This financing is expected to enhance the company's financial position and facilitate future developments. The private placement provides necessary capital that may support future growth and operational initiatives.

Intelligent Bio Solutions Inc. (INBS) experienced a notable decline in its stock price, contributing to its position among the top midday decliners. The company's recent performance has raised concerns among investors, reflecting broader market trends and specific challenges faced by the firm. Analysts are closely monitoring the situation as it unfolds, with implications for future trading and investor sentiment. The stock decline indicates moderate concerns that may affect investor sentiment and financial performance.

Intelligent Bio Solutions Inc. has announced a new manufacturing partnership aimed at enhancing its global production capabilities and improving profit margins. This strategic collaboration is expected to bolster the company's operational efficiency and market competitiveness, positioning it for future growth. The partnership is a significant strategic move that could enhance production capabilities and improve margins, likely impacting future performance.

Intelligent Bio Solutions Inc. (INBS) has announced a $10.0 million private placement priced at-the-market under Nasdaq rules. The offering is expected to enhance the company's financial position and support its growth initiatives. The placement will be conducted through a registered direct offering, allowing the company to raise capital efficiently. The private placement is likely to provide necessary funding for growth but may not significantly alter the company's overall trajectory.

Intelligent Bio Solutions Inc. (INBS) has been highlighted as one of the most active stocks, indicating increased trading volume and investor interest. The company's recent activities and market performance have drawn attention, suggesting potential developments that could influence its future trajectory. Increased trading activity may affect market sentiment and investor interest, but the overall impact on the company's long-term performance is expected to be limited.

Intelligent Bio Solutions Inc. has announced a strategic partnership with Vlepis, a provider of advanced sensing and wearable patch technologies. This collaboration aims to enhance innovation in non-invasive screening and consumer health monitoring, potentially expanding the capabilities and market reach of Intelligent Bio Solutions. The partnership is expected to significantly enhance product offerings and competitive positioning in the health monitoring sector.

Intelligent Bio Solutions Inc. announced a reverse stock split aimed at increasing the per-share price of its common stock. The split ratio is set at 1-for-10, meaning shareholders will receive one new share for every ten shares they currently own. This move is intended to meet the minimum bid price requirement for continued listing on the Nasdaq. The reverse split is expected to take effect on a specified date, with the company emphasizing its commitment to enhancing shareholder value. The reverse stock split may influence market perception and compliance with listing requirements, but its overall impact on long-term performance is expected to be limited.

Intelligent Bio Solutions Inc. (INBS) reported record revenue growth in its fiscal 2026 first quarter, highlighting significant operational achievements. The company showcased advancements in its product offerings and strategic initiatives aimed at enhancing market presence. Financial results indicate a strong upward trajectory, reflecting effective management and innovative solutions in the biotechnology sector. Record revenue growth and operational highlights suggest significant positive momentum for the company's future performance.